Optimal choice of first-line treatment for advanced renal cell carcinoma based on the results of extended follow-up data

doi:10.21037/tau-24-172

Editorial

. 2024 Aug 31;13(8):1336-1340.

doi: 10.21037/tau-24-172. Epub 2024 Aug 12.

Optimal choice of first-line treatment for advanced renal cell carcinoma based on the results of extended follow-up data

Goshi Kitano¹, Takahiro Kojima¹

Affiliations

PMID: 39280655
PMCID: PMC11399020
DOI: 10.21037/tau-24-172

Editorial

Optimal choice of first-line treatment for advanced renal cell carcinoma based on the results of extended follow-up data

Goshi Kitano et al. Transl Androl Urol. 2024.

. 2024 Aug 31;13(8):1336-1340.

doi: 10.21037/tau-24-172. Epub 2024 Aug 12.

Authors

Goshi Kitano¹, Takahiro Kojima¹

Affiliation

¹ Department of Urology, Aichi Cancer Center Hospital, Nagoya, Japan.

PMID: 39280655
PMCID: PMC11399020
DOI: 10.21037/tau-24-172

No abstract available

Keywords: IO-TKI combinations; Immuno-oncology (IO); KEYNOTE-426; tyrosine kinase inhibitor (TKI).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-24-172/coif). The authors have no conflicts of interest to declare.

Figures

**Figure 1**
HR for OS and PFS for each clinical trial over time. HR, hazard ratio; M, months of median follow-up; ITT, intention-to-treat; OS, overall survival; PFS, progression-free survival.

See this image and copyright information in PMC

Comment on

Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, Alekseev B, Pouliot F, Melichar B, Soulières D, Borchiellini D, McDermott RS, Vynnychenko I, Chang YH, Tamada S, Atkins MB, Li C, Perini R, Molife LR, Bedke J, Rini BI. Plimack ER, et al. Eur Urol. 2023 Nov;84(5):449-454. doi: 10.1016/j.eururo.2023.06.006. Epub 2023 Jul 25. Eur Urol. 2023. PMID: 37500340

Similar articles

Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies.
Stühler V, Herrmann L, Maas M, Walz S, Rausch S, Stenzl A, Bedke J. Stühler V, et al. World J Urol. 2022 May;40(5):1175-1183. doi: 10.1007/s00345-022-03960-1. Epub 2022 Feb 26. World J Urol. 2022. PMID: 35217885 Free PMC article.
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Santoni M, Buti S, Myint ZW, Maruzzo M, Iacovelli R, Pichler M, Kopecky J, Kucharz J, Rizzo M, Galli L, Büttner T, De Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Kopp RM, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, Büchler T, Massari F, Seront E, Calabrò F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Bamias A, Caffo O, Procopio G, Sunela K, Bassanelli M, Ortega C, Grillone F, Landmesser J, Milella M, Messina C, Küronya Z, Mosca A, Bhuva D, Santini D, Vau N, Morelli F, Incorvaia L, Rebuzzi SE, Roviello G, Soares A, Bisonni R, Bimbatti D, Zabalza IO, Rizzo A, Mollica V, Sorgentoni G, Monteiro FSM, Battelli N, Bracarda S, Porta C. Santoni M, et al. Eur Urol Oncol. 2024 Feb;7(1):102-111. doi: 10.1016/j.euo.2023.07.003. Epub 2023 Jul 21. Eur Urol Oncol. 2024. PMID: 37481365
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
Santoni M, Massari F, Myint ZW, Iacovelli R, Pichler M, Basso U, Kopecky J, Kucharz J, Buti S, Rizzo M, Galli L, Büttner T, De Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, Büchler T, Seront E, Calabrò F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Bamias A, Caffo O, Procopio G, Bassanelli M, Merler S, Messina C, Küronya Z, Mosca A, Bhuva D, Vau N, Incorvaia L, Rebuzzi SE, Roviello G, Zabalza IO, Rizzo A, Mollica V, Sorgentoni G, Monteiro FSM, Montironi R, Battelli N, Porta C. Santoni M, et al. Target Oncol. 2023 Jul;18(4):559-570. doi: 10.1007/s11523-023-00978-2. Epub 2023 Jun 27. Target Oncol. 2023. PMID: 37369815
Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis.
Wenzel M, Deuker M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Becker A, Roos FC, Chun FKH, Karakiewicz PI. Wenzel M, et al. Eur J Cancer. 2021 Sep;155:245-255. doi: 10.1016/j.ejca.2021.07.014. Epub 2021 Aug 12. Eur J Cancer. 2021. PMID: 34392067
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials.
Rizzo A, Mollica V, Santoni M, Rosellini M, Marchetti A, Massari F. Rizzo A, et al. Future Oncol. 2022 Feb;18(5):625-634. doi: 10.2217/fon-2021-0888. Epub 2021 Dec 20. Future Oncol. 2022. PMID: 34927453 Review.

See all similar articles

References

1. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019;380:1103-15. 10.1056/NEJMoa1816047 - DOI - PMC - PubMed
1. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018;378:1277-90. 10.1056/NEJMoa1712126 - DOI - PMC - PubMed
1. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019;380:1116-27. 10.1056/NEJMoa1816714 - DOI - PubMed
1. Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2021;384:829-41. 10.1056/NEJMoa2026982 - DOI - PMC - PubMed
1. Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med 2021;384:1289-300. 10.1056/NEJMoa2035716 - DOI - PubMed

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- AME Publishing Company
- PubMed Central

[1] Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019;380:1103-15. 10.1056/NEJMoa1816047 - DOI - PMC - PubMed

[2] Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019;380:1103-15. 10.1056/NEJMoa1816047 - DOI - PMC - PubMed

[3] Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018;378:1277-90. 10.1056/NEJMoa1712126 - DOI - PMC - PubMed

[4] Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018;378:1277-90. 10.1056/NEJMoa1712126 - DOI - PMC - PubMed

[5] Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019;380:1116-27. 10.1056/NEJMoa1816714 - DOI - PubMed

[6] Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019;380:1116-27. 10.1056/NEJMoa1816714 - DOI - PubMed

[7] Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2021;384:829-41. 10.1056/NEJMoa2026982 - DOI - PMC - PubMed

[8] Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2021;384:829-41. 10.1056/NEJMoa2026982 - DOI - PMC - PubMed

[9] Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med 2021;384:1289-300. 10.1056/NEJMoa2035716 - DOI - PubMed

[10] Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med 2021;384:1289-300. 10.1056/NEJMoa2035716 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Optimal choice of first-line treatment for advanced renal cell carcinoma based on the results of extended follow-up data

Affiliation

Optimal choice of first-line treatment for advanced renal cell carcinoma based on the results of extended follow-up data

Authors

Affiliation

Conflict of interest statement

Figures

Comment on

Similar articles

References

Publication types

LinkOut - more resources

Full Text Sources